The role of psychological symptoms in recognizing late-onset hypogonadism (LOH) is still controversial. The aim of the study is to evaluate the association between LOH and specific psychological symptoms, and to verify whether investigating intra-psychic domain improves the accuracy of a validated case-history tool (ANDROTEST) in detecting LOH. A consecutive series of 1009 subjects (mean age 49.23±13.34) consulting for sexual dysfunction was studied. Intra-psychic symptoms were investigated by Middlesex Hospital Questionnaire (MHQ), a self-reported questionnaire for screening of mental disorders. A minimum set of two MHQ items was identified through iterative receiver-operating characteristic analysis, with assessment of sensitivity and specificity for hypogonadism (calculated free testosterone o0.225 nmol l À 1 ) in an exploratory sample of 462 patients. Sensitivity and specificity were verified in a validation sample of 547 subjects, in which the final two-item version showed an accuracy of 58.4 ± 3.2% in detecting hypogonadism. The combination of the two-item score with ANDROTEST increased the accuracy in predicting hypogonadism (0.741 ± 0.029; Po0.0001) when compared with ANDROTEST (0.696 ± 0.018; Po0.0001) and the two-item score (Po0.05) alone. Hence, combining these two psychological symptoms with a physical scoring system improves its ability in detecting hypogonadism. The combination of the scores should be tested in other studies.
INTRODUCTION
All cross-sectional and longitudinal studies indicate that a relevant proportion of men over the age of 60 have serum testosterone (T) levels below the lower limits of young adult men. [1] [2] [3] [4] [5] [6] Data from the European Male Aging Study (EMAS), a population-based study involving more than 3000 subjects from 8 European centers, showed an age decline of 1.3% per annum for free T (FT), 1 and this figure is in line with previously published data. 3, 4, 6 Hence, a biochemically defined, age-related androgen deficiency is a very common condition; physicians should become more and more knowledgeable about its nature and symptoms.
The concept of an age-dependent androgen decline is closely linked to late-onset hypogonadism (LOH), 7 a condition characterized by T-deficiency with an unknown etiology and natural history, which often results from a mixed failure of the testis and/or of the hypothalamus-pituitary. 8 LOH recognition has been greatly helped by recent consensus among professional societies, 7, [9] [10] [11] which agree on the necessity that, for diagnosing LOH, low serum T-levels must be associated with consistent symptoms and signs. However, the latter are often mild and insidious, making their recognition problematic. By consensus, the most typical clinical futures associated with T-deficiency are as follows: sexual dysfunctions, decreased lean mass and increased fat mass, osteoporosis and mood changes. 7, 9, 10 Among sexual symptoms, hypoactive sexual desire is considered the most specific, whereas ED is probably the most common hypogonadism-related symptom leading to a medical consultation. [12] [13] [14] Scientific societies do not agree on the biochemical thresholds of androgen levels; for total T, such a threshold varies, in different statements, between 7 and 12 nmol l À 1 (see refs. 7, 9, 10). However, the majority of consensus documents consider FT (as measured by equilibrium dialysis or calculated according to Vermuelen formula) as a useful diagnostic tool for diagnosing LOH, with a threshold ofo0.225 nmol l À 1 (see refs. 7, 9, 10). LOH-related symptoms can be explored by using self-reported questionnaires, specifically developed to help in recognizing them. Available instruments include the following: the St Louis University Androgen Deficiency in Aging Males (ADAM), 15 the Aging Male Scales (AMS), 16 the questionnaire of the Massachusetts Male Aging Study (MMAS) 17 and the most recent New England Research Institute (NERI) Hypogonadism screener. 18 All these inventories have shown a high sensitivity, but low specificity, in predicting hypogonadism. For this reason, current guidelines for detection and management of LOH do not recommend their use for diagnosing hypogonadism. desire and delayed ejaculation), as well as the presence of hypogonadism-related comorbidities, but it does not take into account psychological symptoms. Epidemiological studies report conflicting results on the relationship between hypogonadism and psychological symptoms. 21 Recent data derived from the EMAS study reported a significant association of three psychological symptoms (fatigue, lack of energy and sadness) with both total and calculated FT (cFT). 22 Data from interventional studies are scanty, but a recent meta-analysis of randomized clinical trials showed a significant, positive effect of T-replacement therapy in depressed patients when compared with placebo. 23 These observations suggest a direct role of T in modulating psychological health, and consequently, the appearance of psychological disturbances, such as depression, anxiety, irritability, insomnia, memory impairment or reduced cognitive function, must arouse in the physician the clinical suspicion of androgen deficiency.
The aim of this study is to evaluate the accuracy of psychological symptoms in recognizing androgen deficiency in subjects with sexual dysfunction. Furthermore, we wanted to verify whether the accuracy of our previously validated structured interview ANDROT-EST, based essentially on sexual symptoms and presence of comorbidities, could be improved by combining its results with those of tests specifically investigating intra-psychic symptoms.
PATIENTS AND METHODS
A consecutive series of 1009 men attending our Sexual Medicine and Andrology Outpatient Clinic for sexual dysfunction for the first time (from January 2002 to July 2011) was retrospectively studied. All patients enrolled underwent the usual diagnostic protocol applied to newly referred subjects at the Andrology Outpatient Clinic. All the data provided were collected as part of the routine clinical procedure. As the Italian legislation does not require the approval of Ethics Committee for procedures that are strictly in agreement with usual diagnostic routine clinical procedure, we did not submit our study protocol to the Ethics Committee. However, an informed consent for the study was obtained from all patients. Patients were asked to complete the Middlesex Hospital Questionnaire (MHQ) 24 in its Italian version, 25 a self-reported questionnaire for the screening of the symptoms of mental disorders in a non-psychiatric setting, which provides scores for free-floating anxiety (MHQ-A), phobic anxiety (MHQ-P), obsessivecompulsive traits and symptoms (MHQ-O), somatization (MHQ-S) and depressive symptoms (MHQ-D). The total score of MHQ (SMHQ ¼ sum of scores for MHQ-A, MHQ-P, MHQ-O, MHQ-S and MHQ-D) provides an index of mood and anxious spectrum psychopathology. 24, 25 The first 462 patients (evaluated before 2006; exploratory sample; see also Table 1) were not tested with the use of ANDROTEST. This sample was used as an exploratory sample to assess the associations between individual MHQ items and cFT. Later on, the results obtained in the exploratory sample were validated in a further sample of subjects (studied after 2006; n ¼ 547; validation sample) systematically tested with both the use of MHQ and ANDROTEST 19 structured interview. The two populations were comparable for demographic and clinical characteristics (Table 1) .
ANDROTEST is a 12-item interview previously validated for the screening of hypogonadism in patients with sexual dysfunction. The patient's answer is codified on a 0-3 Likert scale by the interviewer, who does not need a specific training. 19 The score ranges from 1 to 32. A higher score identifies a higher prevalence of hypogonadismrelated symptoms and signs. 19 In particular, we recently demonstrated that a score46 is prognostic of low total T (o8 nmol l , Vermeulen formula) with sensitivity and specificity of 67 and 67, and 64 and 67%, respectively. 20 The occurrence of spontaneous sleep-related erections was investigated using question number 6 of ANDROTEST ('Do you ever wake up with All patients of exploratory and validation samples underwent a complete physical examination, with measurement of blood pressure (mean of three measurements 5-min apart, in sitting position, with a standard sphygmomanometer) and waist circumference. Height and weight were used to calculate body mass index. Blood samples were drawn in the morning, after an overnight fast, for determination of blood glucose (by glucose oxidase method; Aeroset Abbott, Rome, Italy), total cholesterol, high-density lipoprotein cholesterol and triglycerides (by automated enzymatic colorimetric method; Aeroset Abbott), follicle stimulating hormone, luteinizing hormone, total T, prolactin, prostate-specific antigen (by electrochemiluminescent method, Modular Roche, Milan, Italy), sex hormone-binding globulin (modular E170 platform electrochemiluminescence immunoassay; Roche Diagnostics, Mannheim, Germany). Calculated FT was derived using Vermuelen formula as previously described. 26 Data were expressed as mean ± s.d. when normally distributed, and as median (quartiles) for parameters with non-normal distribution, unless otherwise specified. Unpaired two-sided Student's t-tests were used for comparison of means of normally distributed parameters. In all other cases, Mann-Whitney U-test was used for comparisons between groups. Stepwise multiple linear regressions were applied for multivariate analysis, whenever appropriate. All statistical analysis was performed on SPSS for Windows 17.0 (SPSS, Chicago, IL, USA).
RESULTS

Exploratory sample
A significant association with cFT was found for six MHQ items, which are reported in Table 2 . In a multivariate analysis, after adjusting for age and P MHQ (a broader index of general psychopathology), only four items retained a significant association with cFT (see Table 2 ). In two of those items-which were positively associated with cFT-the sign of the score was inverted, to have a unidirectional scoring toward hypogonadism. The sum of scores thus obtained was further tested with iterative receiveroperating characteristic curve analysis to determine the most proper threshold for screening hypogonadism. Then, the items were removed one by one, starting from those with the lower association with hypogonadism, and the analysis described above was repeated iteratively, until the removal of one further item substantially reduced sensitivity and specificity. Figure 1 shows the negative linear relationship between the final two-item score (question numbers 28 and 48) with total T and cFT, which retained significance also after adjusting for age (adjusted r ¼ À 0.162, Po0.001 and adjusted r ¼ À 0.192, Po0.0001, respectively). The receiver-operating characteristic curve analysis (Figure 1 , panel c) for low cFT (o0.225 nmol l À 1 ) indicates that, when a threshold of X2 was chosen, the sensitivity and specificity were 62.6 and 51.6%, respectively, with an accuracy of 0.593 ± 0.035 (Po0.01).
Validation sample When the same threshold (X2) was applied to the validation sample, it showed a high sensitivity (82.8%), but a low specificity In the validation sample, combining the scores of these two items with the ANDROTEST score, the accuracy in predicting low cFT increased (0.741 ± 0.029; Po0.0001), when compared with ANDROTEST (0.696 ± 0.018; Po0.0001; Figure 2 , panels b and a) and the two item score alone. Using the ANDROTEST with the described threshold of 6, sensitivity and specificity for cFT o0.225 nmol l À 1 were 64.2 and 65.3%, respectively. When ANDROTEST was combined with the two additional items, a score of 8 identified patients with cFT o0.225 nmol l À 1 with a sensitivity and a specificity of 69.9 and 66.5%, respectively (Figure 2) . A general linear model was used to examine possible interactions between the score of those two items and ANDROT-EST score on cFT. In an age-adjusted model, we found that both scores independently predict low FT (adjusted r ¼ À 0.337, Po0.01 and adjusted r ¼ À 0.580, Po0.0001; respectively), and that their interaction term positively modulates detection of low cFT (adjusted r ¼ 0.407, Po0.05).
Both samples
When the whole sample (exploratory and validation samples) was considered, subjects with a two-item score X2 more often reported reduced sleep-related erections, sexual desire and ejaculate volume, even after adjusting for age (hazard ratio (HR) ¼ 1.376 (1.049-1.805), Po0.0001; HR ¼ 1.444 (1.049-1.987), Po0.05; and HR ¼ 1.206 (1.017-1.429), Po0.05, respectively; Figure 3 ). Furthermore, in the same model, an increased score was associated with obesity, as defined by a body mass index 430 kg m À 2 (HR ¼ 1.578 (1.094-2.275), Po0.05) and with an increased waist circumference (HR ¼ 1.524 (1.131-2.054), Po0.006; Figure 3) .
No further correlation was observed with the other clinical, metabolic and hormonal parameters evaluated (data not shown).
DISCUSSION
Our study demonstrates that in patients consulting for sexual dysfunction-and therefore symptomatic for LOH-low cFT (o0.225 nmol l ) is specifically associated with distinct, MHQderived, intra-psychic features. Score of these two items were able, per se, to identify a pathological cFT with an acceptable accuracy (60%). Furthermore, the algebraic addition of scores of these MHQderived questionnaire items to scores derived from ANDROTESTstructured interview increases the accuracy of the latter in predicting hypogonadism. As ANDROTEST is a clinician-used and the MHQ is a self-reported tool, the two instruments must be run separately, score-computed and only finally combined.
The association between psychological symptoms and hypogonadism is controversial, mostly because of sample heterogeneity. 27 In fact, different age, health and methodological aspects might bias results. Data from the EMAS study demonstrated an increased prevalence of psychological symptoms, such as sadness and fatigue, when cFT is lower than 0.160 nmol l À 1 (see ref. 22 ). These data are in line with some previous reports, 28, 29 but not confirmed by others. 27, 30 Item number 48 of the MHQ questionnaire ('Do you sometimes find yourself posing or pretending?'), which explores histrionic traits, showed the strongest association with cFT levels. Accordingly, we previously demonstrated that subjects with histrionic/ hysterical traits have a lower prevalence of biochemical and clinical hypogonadism, along with better sexual functioning. By definition, histrionic subjects are characterized by the need to be the center of attention (self-centeredness), inappropriate seductive appearance or behavior, and excess concern with physical appearance. On the other hand, T-levels in men have been associated with different behaviors, including dominance 31,32 and competitiveness. 33 We can hypothesize that a lower inclination to show off or to draw attention could be a typical behavior of hypogonadal men.
Low cFT was also independently associated with feeling fatigued (MHQ-item number 28 'Do you feel unduly tired and exhausted?'). In line with our finding, lack of vitality, lack of energy and tiredness were also included in some of the most commonly used case-history tools for the screening of hypogonadism, such as ADAM, 15 AMS, 16 MMAS 17 and NERI, 18 respectively. In addition, as reported above, fatigue was significantly associated with massderived cFT in the EMAS study. 22 None of the MHQ items assessing free-floating, phobic anxiety and depressive symptoms showed significant correlations with cFT levels. This point deserves further explanation. Although previous studies have reported an association between hypogonadism, anxiety behaviors [34] [35] [36] and depressive symptoms, 29, 37, 38 other authors have not confirmed this association. [39] [40] [41] [42] In addition, it should be recognized that sexual dysfunction, and ED in particular, has been previously associated with depressive symptoms in a bidirectional way. 43 Hence, the possibility that ED might mask the association between depressive symptoms and hypogonadism cannot be excluded.
The ability of the final two-item score in identifying hypogonadal patients was confirmed by the observed correlation between the two-items-MHQ-derived score and other parameters related to reduced androgenization such as reduction of sleep-related erections, 22, 44 reduced sexual desire, 22, 45 perceivedreduced ejaculate volume 46 and obesity. 47 Our two-item test showed an acceptable accuracy (58%) and high sensitivity (82.8%), but a rather low specificity (28.7%), for biochemical hypogonadism. This observation is in line with other commonly used inventories for the screening of hypogonadism (ADAM, AMS, MMAS and NERI Hypogonadism Screener). [15] [16] [17] [18] 20 Accordingly, we recently observed that, in a population of subjects consulting for sexual dysfunction, when different symptoms were considered, they showed a good sensitivity but a low specificity, independent of age and biochemical threshold used for diagnosis of hypogonadism. 20 Consequently, only the association of several symptoms and signs could significantly raise the clinical suspicion of low T. Accordingly, the combination of the two-item score with the ANDROTEST score, investigating sexual symptoms and hypogonadism-related comorbidities was associated with an increased accuracy for predicting hypogonadism in comparison with the original ANDROTEST.
Several limitation should be recognized. First of all, the crosssectional surveys, such as the present one, do not allow any speculation on causal relationship. In fact, the impaired mood and psychological involvement can be caused by the sexual dysfunction, which can also modify T levels. 48 This study is retrospective; for this reason, data were analyzed a posteriori. Furthermore, the psychometric instrument used to assess psychiatric symptoms does not provide diagnoses according to Diagnostic and Statistical Manual of Mental Disorders IV criteria, unlike a structured clinical interview, but is instead designed to detect psychiatric symptoms and traits with a dimensional perspective. In addition, the use of self-reported data, such as in the case of the MHQ questionnaire, is acknowledged to be subject to possible information bias and carries the risk of an oversimplification of the psychiatric problem. 49 Moreover, these results are derived from patients consulting an Andrology Clinic for sexual dysfunction, who could have different characteristics from those consulting general practitioners or other specialists, not seeking medical care or without ED. In fact, results obtained in specific clinical settings cannot be easily generalized to wider populations. Conversely, phenomena observed in samples from the general population cannot always be extended to patients seeking treatment for a specific condition; this means that instruments development in clinical samples could be more reliable in clinical settings in comparison with those designed in general population. It should be also recognized that ANDROTEST 19 was originally validated in its Italian version, and that the adaptation in other languages could require some further validation. However, being a structured interview (in which questions can be rephrased by the investigator and answers are scored by the interviewer rather than chosen by the patients himself on the basis of exact wording), it would be expected that few problems should arise from translations. Finally, it must be recognized that although case-history tools can help the physician in identifying subjects at risk for hypogonadism, the determination of T remains mandatory to confirm the diagnosis of hypogonadism and/or to start any substitutive therapy according to accepted clinical guidelines. 7, 9, 10 In conclusion, our data suggest that psychological disturbances should be rated among the clinical manifestations of hypogonadism, along with sexual and physical symptoms. As both body and mind can suffer from androgen deficiency, exploring only physical symptoms and signs could be limitative. Investigating and recognizing intra-psychic distress could be of help in detecting an androgen deficiency, especially in subjects complaining also of sexual dysfunctions. 50 Hence, the combination of scores on these two psychological symptoms to a physical scoring system (ANDROTEST) further improves its ability in detecting hypogonadism. This combination of scores should be tested in other studies.
